Project Grant R35GM162590
- The National Institute of General Medical Sciences awarded the University of Florida $411,407 on August 15, 2026, to develop a bioanalytical platform for monitoring and modeling sepsis immunopathology under the Biomedical Research and Research Training program (CFDA 93.859). The funded research establishes an integrated platform to capture ultrasensitive, longitudinal biochemical monitoring of immune effectors in sepsis patients and develop dynamic disease models linking biochemical trends to...
- The National Institute of General Medical Sciences awarded the University of Florida $387,845 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a personalized sepsis-risk engine using explainable artificial intelligence and in vitro validation. The research integrates multimodal electronic health record data with high-dimensional omics and mechanistic modeling to identify host pathways that convert neutropenic infection into sepsis and...
- The National Institute of General Medical Sciences awarded Duke University $446,410 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, R01GM163225) to develop and validate statistical methods for identifying disease subtypes in patient populations, with application to sepsis. The project develops three classes of Bayesian statistical approaches designed to address limitations in standard clustering techniques: Bayesian multiview pyramids to handle...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $149,214 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lipid-loaded macrophages in atherosclerotic plaque inflammation. The recipient will characterize the metabolic landscape and cell fate decisions of atheroma-derived macrophages under lipid loading, examining how lipid-associated macrophages release extracellular adenosine triphosphate as a pro-inflammatory signaling...
- Federal Grant Award Summary Mayo Clinic received a $783,661 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion scheduled for August 31, 2026. The award funds a pragmatic, randomized clinical trial evaluating the effectiveness and safety of oral midodrine as a vasopressor-sparing agent in patients with sepsis-associated hypotension. The study seeks to reduce intensive...
- The National Institute of Neurological Disorders and Stroke, a division of the Department of Health and Human Services National Institutes of Health, awarded Mayo Clinic Jacksonville $242,580 on August 24, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to decode and target the molecular mechanisms of TRAF7/KLF4 driver mutations in meningioma. The project uses CRISPR-CAS9 gene editing to introduce...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $593,663 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombolysis resistance in acute ischemic stroke with large vessel occlusion. The project addresses the failure of intravenous thrombolysis with tissue plasminogen activator (TPA) to achieve successful recanalization in most eligible patients. Mayo Clinic will conduct three integrated research activities: define metabolic...
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic Jacksonville $622,792 on May 20, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to identify transcriptomic and genomic signatures distinguishing amyotrophic lateral sclerosis spectrum disorders. The award funds research to characterize dysregulated transcripts and pathways driving upper motor neuron versus lower motor neuron pathology across the...
- The National Institute of General Medical Sciences awarded the University of Wisconsin–Madison $123,309 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop computational methods for improving sepsis diagnosis through plasma metagenomic sequencing. The research addresses the challenge of timely and accurate sepsis diagnosis in critically ill patients by analyzing microbial and host cell-free DNA (cfDNA) in blood plasma. Current diagnostic...
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic Jacksonville $1,879,248 on September 3, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to employ long-read sequencing technologies to identify genomic variation and disease-relevant transcripts contributing to Lewy body dementia and frontotemporal lobar degeneration. The research will detect structural variants, copy number variants,...
The National Institute of General Medical Sciences awarded Mayo Clinic Jacksonville $462,410 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to validate sepsis patient subphenotypes defined by lipoprotein and lipid metabolism profiles and assess their therapeutic utility in precision medicine approaches. The research addresses dysregulated lipoprotein and lipid metabolism in sepsis by validating two novel clinical subphenotypes—hypolipoprotein (HYPO-L) and normolipoprotein (NORMO-L)—that the recipient's team identified in preliminary work. HYPO-L patients, representing approximately 40 percent of sepsis cases, display reduced apolipoprotein A-I and HDL/LDL cholesterol, impaired endothelial function, increased organ dysfunction, elevated mortality, and dysregulation of five key lipid metabolism genes. The funded work will measure a 15-feature clinical and lipid panel in nearly 1,000 samples from the NIH multicenter CLOVERS sepsis trial and University of Florida patient populations to assess subphenotype stability, early phenotype switching within the first 72 hours, and differential treatment responses—factors the recipient identifies as critical for future clinical trial design. Performance occurs in Jacksonville, Florida, with a period of performance from August 1, 2026, through April 30, 2031. The award is classified as a Project Grant, a standard assistance type under NIGMS's investigator-initiated research portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $462.4k | 7/21/26 |